发明名称 PERSONALIZED TREATMENT OF CANCER USING FGFR INHIBITORS
摘要 The present invention relates to a method for predicting the responsiveness of cancer cells to FGFR1 inhibitors, which comprises the evaluation of the status of FGFR1 gene and the status of MYC. A kit useful for carrying out the method is also provided. In addition, a method of treating cancer such as lung cancer is also provided which includes determining the status of FGFR1 gene and the status of MYC gene, and administering to the cancer patient an FGFR1 inhibitor if the tumor tissue or cells exhibit an increased expression or amplification of the FGFR1 gene, as well as an increased expression or amplification of the MYC gene.
申请公布号 US2015335643(A1) 申请公布日期 2015.11.26
申请号 US201514716883 申请日期 2015.05.20
申请人 Thomas Roman K.;Malcher Florian 发明人 Thomas Roman K.;Malcher Florian
分类号 A61K31/506;C12Q1/68 主分类号 A61K31/506
代理机构 代理人
主权项 1. A method of treating cancer comprising administering an effective amount of an FGFR1 inhibitor to a cancer patient, wherein tumor cells or tissue obtained from the patient has been detected to exhibit (1) focal FGFR1 gene amplification or FGFR1 gene overexpression, and (2) MYC gene amplification or MYC gene overexpression.
地址 Cologne DE
您可能感兴趣的专利